低分子量分子によるSARS-CoV-2 RNA トランスレーション・イニシアチブ・エレメントSL1を標的とする
Sabrina Toews1, Francesca Donà2, Marco Keller2
1Institute for Organic Chemistry and Chemical Biology, Center for Biomolecular Magnetic Resonance (BMRZ), Goethe University Frankfurt am Main, 60438 Frankfurt am Main, Hesse, Germany.
Journal of the American Chemical Society
|August 4, 2025
まとめ
研究者は,ウイルスタンパク質合成に不可欠なSARS-CoV-2 RNA幹ループ1 (SL1) を標的とした小分子阻害剤を開発した. NMRによる薬剤化学は,強力な阻害剤を迅速に特定し,ウイルスに対する新しい戦略を示しました.
科学分野:
- 薬剤化学
- ウイルス学
- 分子生物学
背景:
- SARS-CoV-2の5'-末端RNA幹ループ1 (SL1) は,ウイルスタンパク質合成,特に宿主細胞のトランスレーション抑制に不可欠である.
- SL1をターゲットにすることで,SARS-CoV-2に対する新たな抗ウイルス療法を開発する戦略が生まれます.
研究 の 目的:
- SARS-CoV-2 SL1 RNA構造を標的とした低分子量阻害剤を開発する.
- 阻害剤を特定し,最適化するために,NMRによる断片ベースの薬剤発見を活用する.
主な方法:
- 化合物およびRNA検出核磁気共振スペクトロスコーピー (NMR) を使用した断片スクリーニング.
- 溶解性,結合親和性,および特異性を高めるために,初期NMRヒットの繰り返し誘導化.
- 細胞フリートランスレーションアッセイでSL1の抑制に最適化された化合物のインビトロ試験.
主要な成果:
- 2つの強力で選択的な阻害剤,化合物A.2とA.13が特定されました.
- NMRは最適化過程を導き,重要な化合物の性質を監視するのに役立った.
- この研究は,ウイルスの翻訳開始を標的とする小分子阻害剤の急速な開発を成功裏に実証した.
結論:
- NMRによる医薬品化学は,SARS-CoV-2 SL1の小分子阻害剤を迅速に発見するための効果的なアプローチです.
- 特定された化合物は,ウイルスの翻訳を有意かつ選択的に抑制している.
- 化合物の親和性,選択性,および in situ 機能的活性との相関性を理解するには,さらなる調査が必要である.
関連する概念動画
Leaky Scanning
5.2K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.2K
Initiation of Translation
34.5K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
34.5K
Translational Regulation
94
Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...
94
siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
RNA Interference
26.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.4K
Experimental RNAi
6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K


